Quest Diagnostics Inc (NYSE:DGX) Shares Acquired by Toth Financial Advisory Corp

Share on StockTwits

Toth Financial Advisory Corp grew its holdings in Quest Diagnostics Inc (NYSE:DGX) by 7.6% during the 3rd quarter, HoldingsChannel.com reports. The firm owned 53,030 shares of the medical research company’s stock after buying an additional 3,735 shares during the period. Quest Diagnostics accounts for approximately 1.2% of Toth Financial Advisory Corp’s holdings, making the stock its 28th largest holding. Toth Financial Advisory Corp’s holdings in Quest Diagnostics were worth $6,071,000 at the end of the most recent quarter.

Several other institutional investors have also made changes to their positions in the company. State Street Corp lifted its stake in shares of Quest Diagnostics by 2.7% in the 1st quarter. State Street Corp now owns 6,818,798 shares of the medical research company’s stock valued at $547,549,000 after purchasing an additional 179,263 shares during the last quarter. Nuveen Asset Management LLC raised its holdings in shares of Quest Diagnostics by 134.1% in the 2nd quarter. Nuveen Asset Management LLC now owns 1,718,572 shares of the medical research company’s stock valued at $195,849,000 after buying an additional 984,331 shares during the period. Grantham Mayo Van Otterloo & Co. LLC raised its holdings in shares of Quest Diagnostics by 21.5% in the 2nd quarter. Grantham Mayo Van Otterloo & Co. LLC now owns 1,668,003 shares of the medical research company’s stock valued at $190,086,000 after buying an additional 294,903 shares during the period. Bank of New York Mellon Corp raised its holdings in shares of Quest Diagnostics by 0.7% in the 2nd quarter. Bank of New York Mellon Corp now owns 1,058,735 shares of the medical research company’s stock valued at $120,652,000 after buying an additional 6,863 shares during the period. Finally, FMR LLC raised its holdings in shares of Quest Diagnostics by 3.1% in the 2nd quarter. FMR LLC now owns 985,417 shares of the medical research company’s stock valued at $112,298,000 after buying an additional 29,775 shares during the period. 87.23% of the stock is currently owned by institutional investors and hedge funds.

In related news, SVP Michael E. Prevoznik sold 35,591 shares of the company’s stock in a transaction dated Wednesday, October 14th. The stock was sold at an average price of $119.00, for a total value of $4,235,329.00. Following the completion of the sale, the senior vice president now directly owns 75,678 shares of the company’s stock, valued at approximately $9,005,682. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, SVP Catherine T. Doherty sold 58,392 shares of the stock in a transaction that occurred on Wednesday, September 2nd. The stock was sold at an average price of $110.60, for a total value of $6,458,155.20. Following the sale, the senior vice president now directly owns 126,803 shares of the company’s stock, valued at $14,024,411.80. The disclosure for this sale can be found here. 1.49% of the stock is owned by corporate insiders.

Shares of DGX traded up $2.06 during mid-day trading on Friday, reaching $120.20. The company’s stock had a trading volume of 1,807,326 shares, compared to its average volume of 1,545,432. Quest Diagnostics Inc has a 12-month low of $73.02 and a 12-month high of $131.81. The stock has a market cap of $16.14 billion, a PE ratio of 21.81, a price-to-earnings-growth ratio of 0.79 and a beta of 1.22. The company has a debt-to-equity ratio of 0.68, a current ratio of 1.29 and a quick ratio of 1.21. The company’s 50 day moving average is $112.77 and its 200 day moving average is $111.61.

Quest Diagnostics (NYSE:DGX) last announced its earnings results on Thursday, July 23rd. The medical research company reported $1.42 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.41 by $0.01. The firm had revenue of $1.83 billion during the quarter, compared to analysts’ expectations of $1.81 billion. Quest Diagnostics had a return on equity of 13.78% and a net margin of 9.99%. The business’s revenue was down 6.3% on a year-over-year basis. During the same period in the prior year, the firm earned $1.73 EPS. As a group, sell-side analysts anticipate that Quest Diagnostics Inc will post 8.7 EPS for the current fiscal year.

The company also recently announced a quarterly dividend, which will be paid on Wednesday, October 21st. Investors of record on Tuesday, October 6th will be given a $0.56 dividend. The ex-dividend date of this dividend is Monday, October 5th. This represents a $2.24 dividend on an annualized basis and a dividend yield of 1.86%. Quest Diagnostics’s dividend payout ratio (DPR) is presently 34.15%.

DGX has been the topic of several research analyst reports. Credit Suisse Group boosted their price objective on Quest Diagnostics from $126.00 to $128.00 and gave the company a “neutral” rating in a report on Tuesday, July 14th. Bank of America upgraded Quest Diagnostics from a “neutral” rating to a “buy” rating and set a $142.00 price target on the stock in a report on Tuesday, July 14th. BofA Securities upgraded Quest Diagnostics from a “neutral” rating to a “buy” rating and set a $142.00 price target on the stock in a report on Tuesday, July 14th. Mizuho upped their price target on Quest Diagnostics from $114.00 to $144.00 and gave the stock a “buy” rating in a report on Friday, July 24th. Finally, Deutsche Bank Aktiengesellschaft upped their price target on Quest Diagnostics from $140.00 to $150.00 and gave the stock a “buy” rating in a report on Friday, July 24th. One investment analyst has rated the stock with a sell rating, nine have given a hold rating, nine have assigned a buy rating and one has assigned a strong buy rating to the company. The stock has an average rating of “Buy” and an average price target of $126.21.

Quest Diagnostics Profile

Quest Diagnostics Incorporated provides diagnostic testing, information, and services in the United States and internationally. The company develops and delivers diagnostic testing information and services, such as routine testing, non-routine and advanced clinical testing, anatomic pathology testing, and other diagnostic information services.

Recommended Story: Dividend Kings

Want to see what other hedge funds are holding DGX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Quest Diagnostics Inc (NYSE:DGX).

Institutional Ownership by Quarter for Quest Diagnostics (NYSE:DGX)

Receive News & Ratings for Quest Diagnostics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Quest Diagnostics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply